← boardnext 2026-12-31next 2028-04
BCAX
Bicara Therapeuticsdistress 2/10 · well-funded / low risk$27.44-2%today-10% from 52w high
Lead: R/M HNSCC
Revenue
pre-revenue
Liquidity
$657M
Runway
5.7 yrs
Shares 1y
+20%
Price & events
+56.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.9%
1D
-0.6%
1W
+9.8%
1M
+20.1%
3M
+63.9%
6M
+132.7%
1Y
—
2Y
—
5Y
+17.2%
All
Overview
- Market Cap
- $1.80B
- Volume
- 11.33K
- 52 Week Range
- $9.71 – $30.40
- Total Shares
- 65.70M
- Float Shares
- 36.68M
- Short %
- 21.52%
- % Held by Insiders
- 10.14%
- % Held by Institutions
- 104.36%
- RVOL
- 0.01x
Pipeline stages · 2 programs
BCA101, Pembrolizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Ficerafusp alfa, Pembrolizumab (KEYTRUDA®)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12-31 Estimated 50% readout ~2027-01-30 | Phase 1 | BCA101, Pembrolizumab | Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer, Squamous Cell Carcinoma of the Lung, EGFR Amplification, Epithelial Ovarian Cancer, Pancreas Cancer, Cutaneous Squamous Cell Carcinoma, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Squamous Cell Carcinoma of Head and Neck | — | recruiting |
| 2028-04 Estimated 50% readout ~2028-06-15 | Phase 2/3 | Ficerafusp alfa, Pembrolizumab (KEYTRUDA®) | Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | — | recruiting |
Catalyst news & presentations · 8
- 2026-08-11Estimated 45%earningsEarningsEarnings releaseyahoo
- May 21, 2026readoutFicerafusp alfa · Topline data on three-year overall survival and deep responses.SEC 8-K
- first quarter of 2026readoutficerafusp alfa · Declaration of optimal biologic dose for pivotal FORTIFI-HN01 studySEC 8-K
- 2025-12-06conferencedata presentationsecondaryPhase 1/2ficerafusp alfa · Preliminary Phase 1b expansion cohort data presented at ESMO AsiaSEC 8-K
- 1H 2025readoutPhase 1ficerafusp alfa · Updated data from Phase 1b expansion cohort expectedSEC 8-K
- first quarter of 2025conferencedata presentationsecondaryPhase 1/2ficerafusp alfa · Phase 1b expansion cohort data presentation.SEC 8-K
- late Q4 2024 or early Q1 2025trial initiationsecondaryPhase 2/3ficerafusp alfa · Initiation of pivotal FORTIFI-HN01 trial.SEC 8-K
- December 2024trial initiationsecondaryPhase 2/3ficerafusp alfa · FORTIFI-HN01 Phase 2/3 trial initiatedSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-05-12Goldman SachsNeutral
- 2026-05-12Morgan StanleyOverweight
- 2026-05-11GuggenheimBuy
- 2026-03-31Wells FargoEqual-Weight
- 2026-03-31Goldman SachsNeutral
- 2026-03-31WedbushOutperform
Competitors — R/M HNSCC
- PYXSPyxis Oncology, Inc.$166M · D4
Recent news
- 2026-07-20Bicara Therapeutics (BCAX) Corporate presentation Summary - Quartr
- 2026-07-20Bicara Therapeutics (BCAX) Proxy filing Summary - Quartr
- 2026-07-20Bicara Therapeutics (BCAX) Study update Summary - Quartr
- 2026-07-19Bicara Therapeutics (BCAX) Proxy filing Summary - Quartr
- 2026-07-19Bicara Therapeutics (BCAX) Corporate presentation Summary - Quartr
- 2026-07-18Bicara Therapeutics (BCAX) Q1 2026 earnings summary - Quartr
- 2026-07-18Bicara Therapeutics (BCAX) Corporate presentation Summary - Quartr
- 2026-07-15Form 4 Bicara Therapeutics Inc For: 14 July By Investing.com - Investing.com Nigeria
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.